Barrett's esophagus: Prevalence, risk of adenocarcinoma, role of endoscopic surveillance;L'esofago di Barrett: Prevalenza, rischio di adenocarcinoma, ruolo dei programmi di sorveglianza endoscopica

Minerva Chirurgica

Volumn 57, Issue 6, 2002, Pages 819-836

  Zaninotto, Giovanni ^a   Costantini, M ^a   Molena, D ^a   Rizzetto, C ^a   Ekser, B ^a   Ancona, E ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Adenocarcinoma; Barrett's esophagus, epidemiology; Endoscopy

Indexed keywords

ADENOCARCINOMA; AGE; ARTICLE; BARRETT ESOPHAGUS; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER SURVIVAL; CARDIA; CAUCASIAN; COST BENEFIT ANALYSIS; DISEASE ASSOCIATION; DYSPEPSIA; DYSPLASIA; ENDOSCOPIC BIOPSY; ENDOSCOPY; ESOPHAGUS CARCINOMA; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GOBLET CELL; HEALTH SURVEY; HUMAN; INTESTINE METAPLASIA; METAPLASIA; METHODOLOGY; PATIENT MONITORING; POPULATION RISK; PREVALENCE; SEX DIFFERENCE; SURVIVAL RATE; SURVIVAL TIME; ESOPHAGOSCOPY; ESOPHAGUS TUMOR; INCIDENCE; REVIEW; RISK FACTOR;

ADENOCARCINOMA; BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; PREVALENCE; RISK FACTORS;

EID: 0036923883     PISSN: 00264733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (100)

1. Tileston W. Peptic ulcer of the esophagus. Am J Med Sci 1906;132:240-65.
2. Stewart MJ, Hartfall SJ. Chronic peptic ulcer of the esophagus. J Pathol Bact 1929;32:9-14.
3. Lyall A. Chronic peptic ulcer of the esophagus: a report of eight cases. Br J Surg 1937;24:534-47.
4. Allison PR. Peptic ulcer of the oesophagus. Thorax 1948;3:20-42.
5. Barrett NR. Chronic peptic ulcer of the oesophagus and oesophagitis. Br J Surg 1950;38:175-82.
6. Allison PR, Johnstone AS. The oesophagus lined with gastric mucous membrane. Thorax 1953;8:87-101.
7. Spechler SJ. Barrett's esophagus. Semin Oncol 1994;21:431-7.
8. Barrett NR. The lower esophagus lined by columnar epithelium. Surgery 1957;41:881-94.
9. Moersch RN, Ellis FH, McDonald JR. Pathologic changes occurring in severe reflux esophagitis. Surg Gynecol Obstet 1959;108:476-84.
10. Bosher LH, Taylor FH. Haeterotopic gastric mucosa in the esophagus with ulceration and stricture formation. J Thorac Surg 1951;21:306-12.
11. Morson BC, Belcher JR. Adenocarcinoma of the esophagus and ectopic mucosa. Br J Cancer 1952;6:127-30.
12. Paull A, Trier JS, Dalton MD, Camp RC, Loeb P, Goyal RK. The histologic spectrum of Barrett's esophagus. N Engl J Med 1976;295:476-80.
13. Skinner DB, Walther BC, Riddell RH, Schmidt H, Iascone C, De Meester TR. Barrett's esophagus: Comparison of benign and malignant cases. Ann Surg 1983;198:554-66.
14. Spechler SJ, Zeroogian JM, Antonioli AM, Wang HH. Prevalence of metaplasia at the gastro-esophageal junction. Lancet 1994;344:1533-6.
15. Weston AP, Krmpotich P, Makdisi WF, Cherian R, Dixon A, McGregor DH et al. Short segment Barrett's esophagus: Clinical and histological features associated endoscopic findings, and association with gastric intestinal metaplasia. Am J Gastroenterol 1996;91:981-6.
16. Nandurkar S, Talley NJ, Martin CJ, Ng TH, Adams S. Short segment Barrett's oesophagus: Prevalence, diagnosis and associations. Gut 1997;40:710-5.
17. Johnston M, Hammond SA, Laskin W, Jones M. Prevalence of clinical characteristics of short segment of specialized intestinal metaplasia in the distal esophagus on routine endoscopy. Am J Gastroenterol 1996;91:1507-11.
18. Sampliner RE. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's Esophagus. The Practice Parameters Committee of The American college of Gastroenterology. Am J Gastroenterol 1998;93:1028-32.
19. Nandurkar S, Talley N. Barrett's Esophagus: the long and the short of it. Am J Gastroenterol 1999;93:30-40.
20. Spechler SJ, Sperber H, Doos WG, Schimmel EM. The prevalence of Barrett's Esophagus in patients with chronic peptic esophageal strictures. Dig Dis Sci 1983;28:769-74.
21. Mann NS, Tsai MF, Nair PK. Barrett's Esophagus in patients with symptomatic reflux esophagitis. Am J Gastroentreol 1989;84:1494-6.
22. Gruppo Operativo per lo Studio delle Precancerosi dell'Esofago (GOSPE). Barrett's Esophagus: epidemiological and clinical results of a multicentric survey. Int J Cancer 1991;48:364-8.
23. Cameron AJ, Lomboy CT. Barrett's Esophagus: age, prevalence and extent of columnar epithelium. Gastroenterology 1992;103:1241-5.
24. Cameron AJ, Zinsmeister JM, Ballard DJ, Carney JA. Prevalence of columnar-lined epithelium. Gastroenterology 1990;99:918-22.
25. Byrne JP Bhatnagar S, Hamid B, Amstrong GR, Attwood SEA. Comparative study of intestinal metaplasia and mucin staining at the cardia and esophagogastric junction in 225 symptomatic patients presenting for the diagnostic open-access gastroscopy. Am J Gastroenterol 1999;94:98-103.
26. Donahue D, Navab F. Significance of short segment Barrett's esophagus. J Clin Gastroenterol 1997;25:480-4.
27. Morales TG, Sampliner RE, Bhattacharyya A. Intestinal metaplsia of the gastric cardia. Am J Gastroenterol 1997;92:414-8.
28. Voutilainen M, Farkkila M, Juhola M, Nuorva K, Mauranen K, Manytynen T et al. Specializaed columnar epithelium of the esophagogastric junction. Prevalence and associations. Am J Gastroenterol 1999;94:913-8.
29. Fireman Z, Wagner G, Weismann J, Kopelman Y, Wagner Y, Groissman G et al. Prevalence of short-segment Barrett's epithelium. Dig Liver Dis 2001;33:322-5.
30. Zaninotto G, Avellini C, Barbazza R, Baruchello G, Battaglia G, Benedetti E et al. Prevalence of intestinal metaplasia: in the distal oesophagus, oesophagogastric juction and gastric cardia in symptomatic patients in north-east Italy: a prospective, descriptive survey. The Italian Study Group "GISU". Dig Liver Dis 2001;33:316-21.
31. Eloubeidi MA, Provenzale D. Does this patient have Barrett's Esophagus? The utility of predicting Barrett's Esophagus at the index endoscopy. Am J Gastroenterol 1999;64:37-43.
32. Smith AM, Maxwell-Armstrong CA, Welch NT, Scholefield JH. Surveillance of Barrett's oesaphagus in the UK. Br J Surg 1999;86:276-80.
33. Ruol A, Parenti A, Zaninotto G, Merigliano S, Costantini M, Cagol M et al. Intestinal metaplasia is the probabile common precursor of adenocarcinoma in Barrett's Esophagus and adenocarcinoma of the gastric cardia. Cancer 2000;88:2520-8.
34. Conio M, Cameron AJ. Intestinal metaplasia is the probable common precursor of adenocarcinoma in Barrett's Esophagus and adenocarcinoma of the gastric cardia. Gastrointestinal Endosc 2001;54:799-801.
35. Clark WB, Smyrk TC, Burdiles P, Hoeft SF, Peters JH, Kiyabu M et al. Is Barrett's metaplasia the source of adenocarcinoma? Arch Surg 1994;129:609-14.
36. Cameron AJ, Lomboy TC, Pera M, Carpenter HA. Adenocarcinoma of the esophagogastric junction and Barrett's esophagus. Gastroenterology 1995;109:1541-6.
37. Jankowski JA, Provenzale D, Moayyedi P. Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west. Gastroenterology 2002;122:588-95.
38. Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric cancer in the United States. Cancer 1998;83:2049-53.
39. Jankowski J. CRC CancerStats: Oesophageal Cancer. London, England: Cancer Research Campaign Press; 2001.
40. Ruol A. (dati non pubblicati).
41. Falk GW, Richter JE. Why is esophageal adenocarcinoma increasing in incidence? Abdom Imaging 1998;23:539-42.
42. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 1985;313:857-9.
43. Hameeteman W, Tygat GN, Houthoff HJ, van den Tweel JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989;96:1249-56.
44. Kelty CJ, Ackroyd R. Cancer risk and Barrett's esophagus. Am J Med 2002;112:507.
45. Schnell TG, Sontag SJ, Chejfec G, Aranha G, Metz A, O'Connell S et al. Long term nonsurgical management of Barrett's esophagus with high grade dysplasia. Gastroenterology 2001;120:1607-19.
46. Shaheen NJ, Crosby MA, Bomzyski EM, Sandler RS. Is there a publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000;199:333-8.
47. Savary M, Ollyo JB, Monnier P. Frequency and importance of endobrachyesophagus in reflux disease. In: Siewert JR, Holscher AH, editors. Disease of the Esophagus. Berlin-New York: Springer Verlag; 1984. p.529-36.
48. Spechler SJ, Robbins AH, Rubins HB, Vincent ME, Heeren T, Doos WG et al. Adenocarcinoma and Barrett's Esophagus. An Overrated Risk? Gastroenterology 1984;87:927-33.
49. Cooper BT, Barbezat GO. Barrett's oesophagus: a clinical study of 52 patients. QJM 1987;62:97-108.
50. Robertson CS, Mayberry JF, Nicholson DA, James PD, Atkinson M. Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus. Br J Surg 1988;75:760-3.
51. Achkar E, Carey W. The cost of surveillance for adenocarcinoma complicating Barrett's esophagus. Am J Gastroenterol 1988;83:291-4.
52. Skinner DB. The incidence of cancer in Barrett's esophagus varies according to the series. In: Giuli R, McCallum RW, editors. Benign Lesions of the Esophagus and Cancer. Berlin: Springer Verlag; 1989. p.764-65.
53. Van der Veen AH, Dees J, Blankensteijn JD, Van Blankenstein M. Adenocarcinoma in Barrett's oesophagus: an overrated risk. Gut 1989;30:14-8.
54. Ovaska J, Miettien M, Kivilaakso E. Adenocarcinoma arising in Barrett's esophagus. Dig Dis Sci 1989;34:1336-9.
55. Polepalle SC, McCallum RW. Barrett's esophagus. Current assessment and future perspectives. Gastroenterol Clin North Am 1990;19:733.
56. Williamson WA, Ellis FH, Gibb SP, Shahian DM, Aretz HT, Heatley GJ et al. Barrett's esophagus. Prevalence and incidence of adenocarcinoma. Arch Intern Med 1991;151:2212-6.
57. Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut 1991;32:1441-6.
58. Watson RGP, Porter KG, Sloan JM. Incidence of adenocarcinoma in Barrett's oesophagus and an evaluation of endoscopic surveillance. Eur J Gastroenterol Hepatol 1991;3:159-62.
59. Iftikhar SY, James PD, Steele RJ, Hardcastle JD, Atkinson M. Length of Barrett's oesophagus: an important factor in the development of dysplasia and adenocarcinoma. Gut 1992;33:1115-58.
60. Bartlesman JF, Hameeteman W, Tytgat GN. Barrett's oesophagus. Eur J Cancer Prev 1992;1:323-5.
61. Reid BJ, Blount PL, Rubin CE, Levine DS, Haggitt RC, Rabinovitch PS. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology 1992;102(Suppl 4 vol 1):1212-9.
62. Moghissi K, Sharpe DA, Pender D. Adenocarcinoma and Barrett's oesophagus: a clinico-pathological study. Eur J Cardiothorac Surg 1993;7:126-31.
63. Bonelli L. Barrett's esophagus: results of a multicentric survey. GOSPE (Gruppo Operativo per lo Studio delle Precancerosi Esofagee). Endoscopy 1993;25:652-4.
64. Ortiz A, Martinez de Haro LF, Parrilla P, Morales G, Molina J, Bermejo J et al. Conservative treatment versus antireflux surgery in Barrett's oesophagus: long-term results of a prospective study. Br J Surg 1996;83:274-8.
65. Van der Burgh A, Dees J, Hop WC, Van Blankenstein M. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996;39:5-8.
66. McDonald ML, Trastek VF, Allen MS, Deschamps C, Pairolero PC. Barrett's esophagus: does an antireflux procedure reduce the need for endoscopic surveillance? J Thorac Cardiovasc Surg 1996;11:1135-8.
67. Wright TA, Graqy MR, Morris AI, Gilmore IT, Ellis A, Smart HL et al. Cost effectiveness of detecting Barrett's cancer. Gut 1996;39:574-9.
68. Weston AP, Krmpotich PT, Cherian R, Dixon A, Topalovski M. Prospective evaluation of intestinal metaplasia and dysplasia within the cardia of patients with Barrett's esophagus. Dig Dis Sci 1997;42:597-602.
69. Drewitz DJ, Sampliner RE, Garewall HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997;92:212-5.
70. Ferraris R, Bonelli L, Conio M, Fracchia M, Lapertosa G, Aste H. Incidence of Barrett's adenocarcinoma in an italian population: an endoscopic surveillance programme: GOSPE (Gruppo Operativo per lo Studio delle Precancerosi Esofagee) Eur J Gastroenterol Hepatol 1997;9:881-5.
71. Katz D, Rothstein R, Schned A, Dunn J, Seaver K, Antonioli D. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's Esophagus. Am J Gastroenterol 1998;93:536-41.
72. Streitz JM Jr, Ellis FHJ, Tilden RL, Erickson RV. Endoscopic surveillance of Barrett's: a cost effectiveness comparison with mammographic surveillance for breast cancer. Am J Gastroenterol 1998;93:911-5.
73. Csendes A, Braghetto I, Burdiles P, Puente G, Korn O, Diaz JC et al. Longterm results of classic antireflux surgery in 152 patients with Barrett's esophagus: clinical, radiologic, endoscopic, manometric, and acid reflux test analysis before and late after operation. Surgery 1998;126:645-57.
74. O'Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol 1999;94:2037-42.
75. Rana PS, Johnston DA. Incidence of adenocarcinoma and mortality in patients with Barrett's oesophagus diagnosed between 1976 and 1986: implications for endoscopic surveillance. Dis Esophagus 2000;13:28-31.
76. Bani-Hani K, Sue-ling H, Johnston D, Axon AT, Martin IG. Barrett's oesophagus: results from a 13 year surveillance programme. Eur J Gastroenterol Hepatol 2000;12:649-54.
77. Eckardt VF, Kanzler G, Bernhard G. Life expectancy and cancer risk in patients with Barrett's esophagus: a prospective controlled investigation. Am J Med. 2001;111:33-7.
78. Spechler SJ, Lee E, Ahnen D, Goyal RK, Hirano I, Ramirez F et al. Long term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001;285:2331-8.
79. Jankowski J. High risk oesophageal lesions: incidence and pathophysiology. In: Gastroesophageal Disease. London: Blackwell; 2001.
80. Chalasani N, Wo JM, Waring JP. Racial differences in the histology, location and risk factors of esophageal cancer. J Clin Gastroenterol 1998;26:11-3.
81. Bersentes K, Fass R, Padda S, Cynthia J, Sampliner RE. Prevalence of Barrett's Esophagus in Hispanics is similar to caucasians? Dig Dis Sci 1998;43:1038-41.
82. Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 2002;122:633-40.
83. Thomas P, Doddoli C, Lienne P, Morati N, Thirion X, Garbe L et al. Changing patterns and surgical results in adenocarcinoma of the oesophagus. Br J Surg 1997;84:119-25.
84. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multinodal therapy and surgery for esophageal adenocarcinoma. New Engl J Med 1996;335:462-7.
85. Incarbone R, Bonavina L, Saino G, Bona D, Peracchia A. Outcome of esophageal adenocarcinoma detected during endoscopic biopsy surveillance for Barrett's esophagus. Surg Endosc 2002;16:263-6.
86. Van Sandick JW, Van Lanschot JJB, Kuiken BW, Tytgat GN, Offerhaus GJ, Obertop H. Impact of endoscopic biopsy surveillance of Barrett's esophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 1998;43:216-22.
87. Peters JH, Clark GWB, Ireland AP, Chandrasoma P, Smyrk TC, DeMeester TR. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg 1994;108:813-22.
88. ElKhoury J, Sahai AV. Endoscopy in Barrett's Esophagus. Chest Surg North Am 2002;12:47-58.
89. Zaninotto G, Parenti AR, Ruol A, Costantini M, Merigliano S, Ancona E. Oesophageal resection for high-grade dysplasia in Barrett's oesophagus. Br J Surg. 2000;87:1102-5.
90. Van Sandick JW, Bartelsman JF, van Lanschot JJ, Tytgat GN, Obertop H. Surveillance of Barrett's oesophagus: physicians' practices and review of current guidelines. Eur J Gastroenterol Hepatol 2000;12:111-7.
91. Falk GW, Ours TM, Richter JE. Practice patterns for surveillance of Barrett's esophagus in the United States. Gastrointest Endosc 2000;52:197-203.
92. Macdonald CE, Wicks AC, Playford RJ. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study. BMJ 2000;18;321:1252-5.
93. Fitzgerald RC, Saeed IT, Khoo D, Farthing MJ, Burnham WR. Rigorous surveillance protocol increases detection of curable cancers associated with Barrett's esophagus. Dig Dis Sci 2001;46:1892-8.
94. Dulai GS. Surveying the case for surveillance. Gastroenterology 2002;122:820-3.
95. Cancer Facts and Figures 2001. Atalanta: American Cancer Society; 2001.
96. Falk GW. Barrett's Esophagus. Gastroenterology 2002;122:1569-91.
97. Sonnenberg A, El-Serag HB. Economic aspects of endoscopic screening for intestinal precancerous conditions. Gastrointest Endosc Clin N Am 1997;7:165-84.
98. Provenzale D, Schmitt C, Wong JB. Barrett's Esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999;94:2043-53.
99. Caygill CP, Reed PI, Watson A, Hill MJ. The UK National Barrett's Oesophagus Registry (UKBOR): aims and progress. Eur J Cancer Prev 2001;10:97-9.
100. Gudlaugsdottir S, van Blankenstien M, Dees J, Wilson PJH. A majority of patients with Barrett's oesophagus are unlikely to benefit from endoscopic cancer surveillance. Eur J Gastroenterol Hepatol 2001;13:639-45.